QUE Oncology, Inc. is a clinical stage company developing drugs for large unmet medical needs. The Company was founded in 2013 by The University of Queensland’s (UQ) main commercialisation company, UniQuest Pty Ltd and Emory University, with both parties providing seed investment and support prior to the Series A financing. QUE Oncology’s lead program is Q-122, a novel non-hormonal treatment for hot flashes in breast cancer survivors undergoing endocrine therapy. Q-122 is an orally bioavailable small molecule and has previously demonstrated an excellent safety profile. Given these very encouraging study outcomes, QUE has accelerated development of Q-122 as a treatment for vasomotor symptoms in breast cancer survivors taking tamoxifen or an aromatase inhibitor. QUE has commenced a Phase 2 study currently being conducted across clinical sites in the US, Australia and New Zealand. Results from this trial will be available in 2020.